Customized Rodent Models of Age-related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is a leading cause of vision loss among the elderly, characterized by the degeneration of the macula, the central part of the retina responsible for sharp vision. The complexity of AMD necessitates the development of effective preclinical models to study its pathophysiology and evaluate potential therapeutic interventions. At Ace Therapeutics, we specialize in providing comprehensive solutions for the development of rodent models that recapitulate the complex pathology of AMD.

Overview of AMD and Related Rodent Models

AMD can be classified into two principal forms: dry (non-exudative) AMD and wet (exudative) AMD.

Dry AMD: Characterized by the accumulation of drusen and gradual retinal degeneration, dry AMD typically progresses slowly and is associated with changes in the retinal pigment epithelium (RPE). Early stages may be asymptomatic, making timely intervention challenging.
Wet AMD: This form is marked by choroidal neovascularization (CNV), where abnormal blood vessels grow beneath the retina, leading to rapid vision loss. Wet AMD can progress quickly, necessitating prompt therapeutic strategies to preserve vision.

The multifactorial nature of AMD involves various risk factors, including genetic predisposition, oxidative stress, inflammation, and environmental influences such as diet and light exposure. Rodent models are invaluable in this disease as they allow researchers to manipulate specific genetic and environmental factors, thereby mimicking the pathophysiological features of AMD observed in humans. These models provide a platform for studying disease mechanisms, testing potential therapies, and understanding the complex interactions between different biological pathways involved in AMD.

Fig 1. A schematic illustration highlighting the stages of age-related macular degeneration (AMD) along with its associated risk factors. Fig. 1. A schematic diagram featuring the stages of age-related macular degeneration (AMD) with its associated risk factors. (Soundara Pandi SP, et al., 2021)

Service Overview

At Ace Therapeutics, the commitment to advancing AMD research is reflected in the development of customized rodent models tailored to the specific needs of researchers. Our Experts utilize cutting-edge techniques, including CRISPR gene editing, transgenic modifications, and drug induction methods, to recapitulate the various aspects of AMD. By providing these specialized models, Ace Therapeutics empowers researchers to explore the nuances of AMD pathology and evaluate therapeutic interventions effectively.

Explore Ace Therapeutics' Rodent Models of AMD

We provide a comprehensive suite of services for the development and validation of AMD rodent models. Our expertise lies in developing models that closely mimic human AMD, supporting the discovery and evaluation of novel therapeutics.

Laser-Induced Choroidal Neovascularization
Our expertise in laser photocoagulation allows us to precisely induce CNV, mimicking the pathological hallmarks of wet AMD. This well-established model is valuable for evaluating the efficacy of anti-VEGF agents and other novel therapies. We provide comprehensive assessment services, including fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) imaging, to thoroughly characterize treatment response and neovascularization changes. With extensive experience in this model, we provide reliable and insightful data to support your drug development programs.
Drug-Induced Dry AMD
We also provide sodium iodate (NaIO₃)-induced models for studying dry AMD. This method involves the intravenous injection of NaIO3, which induces RPE degeneration and photoreceptor loss. The resulting phenotype is characterized by progressive retinal damage, making it an effective model for exploring potential neuroprotective therapies. We support clients to evaluate the effects of various drug candidates on retinal integrity and function using electrophysiological assessments, including electroretinography (ERG).

Gene-Editing Services for AMD Research

We utilize gene-editing technologies, including CRISPR/Cas9, to create knockout (KO), knockin (KI), and transgenic (TG) mouse models. These models are designed to target specific genes implicated in AMD, such as VEGFA, which plays a critical role in neovascularization. By modifying these genes, we can investigate the molecular pathways involved in AMD development and progression.

Ace Therapeutics is dedicated to providing customized models that enable comprehensive research into the mechanisms of AMD and the exploration of potential therapeutic strategies. For more information about our customized rodent models and how we can assist you in your AMD research, please do not hesitate to contact us.

Reference

Soundara Pandi SP, et al. Progress in developing rodent models of age-related macular degeneration (AMD). Exp Eye Res. 2021;203:108404.

For Research Use Only.